Aprepitant vs Desloratadine for EGFR-TKI–Induced Pruritus in Patients With NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial
Cancer 2022 Oct 05;[EPub Ahead of Print], T Zhou, Y Zhang, Y Ma, W Ma, X Wu, L Huang, W Feng, H Zhou, J Liu, H Zhao, L Zhang, Y Yang, Y HuangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.